ASH 2020 | Long term follow-up results from the Phase III MAIA trial in myeloma
Aurore Perrot, MD, University of Toulouse, Toulouse, France, shares updated findings from the Phase III MAIA study (NCT02252172): a trial of daratumumab, lenalidomide and dexamethasone (D-Rd), in comparison to Rd in transplant-ineligible newly diagnosed multiple myeloma. In the primary analysis of the MAIA study, adding the anti-CD38 monoclonal antibody daratumumab to Rd resulted in substantially improved progression-free survival and measurable residual disease-negativity rates. After 4-years of follow-up, the primary endpoint of progression-free survival continued to be met and was consistently improved across all analyzed subgroups. Responses were still found to be deeper and more durable with added daratumumab. Rates of discontinuation owing to disease progression were significantly higher in the Rd arm, supporting the use of D-Rd in this patient population. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
